PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

Author
Azad, Abul
Arshad, Maryam
Generali, Daniele
Feldinger, Katharina
Gijsen, Merel
Strina, Carla
Cappelletti, Mariarosa
Andreis, Daniele
Leek, Russell
Haider, Syed
Publication date
2024-11-24
Subject
Oncology. Pathology.
Microbiology. Immunology

Metadata
Show full item record
Abstract
No abstract available
Citation
Azad A, Arshad M, Generali D, Feldinger K, Gijsen M, Strina C, Cappelletti M, Andreis D, Leek R, Haider S, Kellokumpu-Lehtinen PL, Roxanis I, Harris AL, Shaaban AM, Joensuu H, Kong A. PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer. Cancer Commun (Lond). 2024 Nov 24. doi: 10.1002/cac2.12632. Epub ahead of print.
Type
Correspondence
Handle
http://hdl.handle.net/20.500.14200/6926
Additional Links
https://onlinelibrary.wiley.com/journal/25233548
DOI
10.1002/cac2.12632
PMID
39582148
Journal
Cancer Communications
Publisher
Wiley
Collections